Incubation of adult rat cardiac myocytes with increasing glucose concentrations decreased phosphorylation (αThr 172 ) and activity of AMPK (AMP-activated protein kinase). The effect could be demonstrated without measurable changes in adenine nucleotide contents. The glucose effect was additive to the decrease in AMPK activity caused by insulin, was attenuated by adrenaline, was not mimicked by glucose analogues, lactate or pyruvate and was not due to changes in myocyte glycogen content. AMPK activity was decreased by xylitol and PMS (phenazine methosulfate) and was increased by the glucose-6-phosphate dehydrogenase inhibitor DHEA (dehydroepiandrosterone) and by thiamine. PMS and DHEA respectively, increased and decreased CO 2 formation by the PPP (pentose phosphate pathway). AMPK activity was inversely related to the myocyte content of Xu5P (xylulose 5-phosphate), an intermediate of the non-oxidative arm of the PPP . Endothall, an inhibitor of PP2A (protein phosphatase 2A), abolished the glucose effect on AMPK activity. Further studies are needed to define the 'active component' that mediates the glucose effect and whether its site of action is PP2A.
INTRODUCTION
AMPK (AMP-activated protein kinase) is a heterotromeric (αβγ ) serine/threonine protein kinase that is a regulator of energy homoeostasis at the cellular and the whole-body level [1, 2] . AMPK is activated during energy stresses such as fuel or oxygen starvation, resulting in the down-regulation of ATP-consuming processes and the turning on of ATP-generating pathways. The increase in cellular AMP/ATP following energy stress leads to allosteric activation of AMPK through an increase in the binding of AMP to CBS (cystathionine β-synthase) domains within its γ -subunit. In mammalian cells, AMPK is also covalently activated by phosphorylation of Thr 172 in the activation loop of the catalytic α-subunit by several upstream AMPK kinases that to date have been identified as LKB1, the calmodulin-dependent kinase kinases and TAK1 [TGF (transforming growth factor)-β-activated kinase 1]. A further consequence of the binding of AMP at the AMPK γ -subunit is to make the αThr 172 site a poorer substrate for PP2A and PP2C, thereby increasing the cellular steady
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state phosphorylation of the AMPK [3] . Other layers of control of the phosphorylation status of mammalian AMPK are independent of changes in cellular AMP/ATP. Many neuro-endocrine factors, including insulin [4] , alter AMPK activity in a tissue-dependent fashion [5] . Also the AMPK system can sense the relative availabilities of carbohydrate and lipid metabolic fuels. In skeletal muscle, increased glucose concentration causes decreased activity/phosphorylation of AMPK [6] and AMPK is allosterically and covalently deactivated by an increase in the cellular glycogen store [7] . By contrast, long-chain fatty acids increase AMPK activity/phosphorylation in perfused rat heart [8] and in skeletal muscle cells [9] .
The activity of ACC-2 (acetyl-coA carboxylase-2), the muscle isoform of ACC, is decreased following phosphorylation by AMPK. Malonyl-CoA, the product of the ACC reaction, allosterically inhibits CPT-1 (carnitine palmitoyltransferase-1), a major regulatory enzyme for fatty acid β-oxidation. The operation of this AMPK/CPT-1 axis plays a key role in the selection and usage of metabolic fuels in response to changing availability of nutrients by both skeletal and cardiac muscles, during contraction of skeletal muscle and in response to anoxia, ischaemia and during post-ischaemic reperfusion in the heart (see [10] for a review). Hamilton and Saggerson [11] found that glucose increased the malonyl-CoA content of cardiac myocytes. This would oppose the action of the Randle Cycle through which the oxidative utilization of carbohydrate fuel is reduced by increased availability of fatty acid. Likewise, the malonyl-CoA content of rat skeletal muscle was increased with increasing glucose concentration and that increase was linked to decreases in both AMPK activity and the phosphorylation of ACC without any changes in the tissue contents of ATP, ADP or AMP [6] .
The initial purpose of the present study was to investigate whether cardiac muscle AMPK activity also was decreased by an increase in glucose concentration. We opted to use isolated ventricular myocytes rather than the perfused heart as the experimental system, partly for continuity with the previous work [11] , but mainly because the myocyte system permitted a range of conditions to be studied within the same experiment. We found that AMPK activity/phosphorylation and ACC phosphorylation were decreased with increasing glucose concentration under conditions where there were no measurable changes in cellular ATP, ADP or AMP contents. We conducted experiments aimed at the identification of the 'active component' that triggers dephosphorylation of AMPK in response to glucose and found that AMPK activity was responsive to changes in the activity of the PPP (pentose phosphate pathway).
EXPERIMENTAL

Materials
General chemicals and enzymes were obtained from Calbiochem, Fluka, Merial, Roche, Sigma-Aldrich or Worthington. SAMS peptide was from Cambridge Research Biochemicals. Radiochemicals were from NEN or from American Radiolabeled Chemicals. Antibodies were obtained as follows. Anti-α-2 AMPK was from Santa Cruz Biotechnology. Antiphospho-Thr 172 α-AMP, anti-phospho-Ser 485/ Ser 491 α-AMPK, anti-total AMPK α-1/α-2-subunits, anti-phospho-Ser 79 ACC-1, anti-total ACC (primary antibodies, all raised in rabbit) and horseradish peroxidase-linked anti-rabbit secondary antibody were from Cell Signaling Technology. Electrophoresis reagents were from Invitrogen. Sodium palmitate was pre-bound to BSA [8] .
Animals
These were male Sprague-Dawley rats aged 6-8 weeks (body weight range, 250-300 g) maintained at [20] [21] [22] • C on a 13 h/11 h light/dark cycle with light from 06:00 h. These had constant access to water and a diet consisting, by weight, of 21 % protein, 4 % fat and 39 % starches and sugars. All procedures had received institutional ethical approval and were licensed under U.K. Home Office regulations for animal experimentation.
Isolation of cardiac ventricular myocytes
Myocytes were isolated as described elsewhere [12] 4 ) containing BSA (20 mg/ml) and 5 mM glucose (incubation buffer). The percentage viability of myocytes was assessed using a haemocytometer. Cells were only considered to be viable if they displayed an elongated rod-shaped morphology with visible cross striations and also excluded Trypan Blue stain (0.4 %, w/v). Cells or cell-like structures that excluded Trypan Blue but were shortened by hypercontracture or exhibited a spherical morphology with no distinct ultrastructure were not considered to be viable, but were included in the total count. Preparations with less than 70 % initial viability by these criteria were discarded. In preliminary experiments (n = 4, results not shown), cells had a linear rate of CO 2 formation from 5 mM [U-
14 C]glucose for at least 60 min with no significant decrease in viability.
Incubation of cardiac myocytes
Prior to incubations, the cell stock was centrifuged for 1 min at 500 g. The cell pellet was resuspended in the original volume of incubation buffer but with glucose omitted. Then, 0.5 ml aliquots of this 'glucose-free' cell stock were added to a further 2 ml of incubation buffer containing the desired glucose concentration together with other additions. For measurements of enzyme activities, protein phosphorylation and metabolite contents the incubations were in sealed 18 ml plastic scintillation vials that were shaken at 37
• C with continuous gassing with O 2 /CO 2 (19:1). At the end of the incubation, which normally was for 1 h, the cells were centrifuged for 1 min at 500 g and washed twice with BSA-free incubation buffer before snap-freezing in liquid nitrogen. For measurements of glucose oxidation, the cells were incubated, as above, at 37
• C in a total volume of 2.5 ml but in 50 ml sealed silicone-treated glass metabolic flasks fitted with centre wells. Gassing with O 2 /CO 2 was only for the first 5 min. Incubations were terminated by the injection of 0.2 ml of 10 M HClO 4 and 0.5 ml of 1 M benzethonium hydroxide into the flask outer compartment and centre well respectively. Evolved 14 CO 2 trapped in the centre well during a subsequent incubation at 37
• C for 1 h was quantified by liquid-scintillation counting.
Measurement of α-2 AMPK activity
Frozen myocytes were sonicated for 3×7 s in 0.5 ml of ice-cold lysis buffer [50 mM Tris/HCl (pH 7.5), 50 mM NaF, 5 mM Na 4 P 2 O 7 , 1 mM EDTA, 1 mM EGTA, 10 % (v/v) glycerol, 1 % (v/v) Triton X-100, 1 mM DTT (dithiothreitol), 1 mM benzamidine, 1 mM PMSF and soya bean trypsin inhibitor (4 μg/ml)]. The lysate was centrifuged at 13 000 g for 10 min at 4
• C, and 60 μl of the resulting supernatant was incubated with anti-α-2 AMPK antibody pre-bound to Protein G-Sepharose. The immunoprecipitates were collected by centrifugation (1 min at 5200 g) and washed/re-centrifuged once with 0.2 ml of lysis buffer 
Western blotting
Myocyte lysates were prepared as for AMPK assays and proteins in 15-25 μl of the 13 000 g supernatant were separated by SDS/PAGE and transferred on to PVDF membranes. Blottings for the detection of phospho-AMPK and phospho-ACC were as described previously [8] , except that BSA (50 mg/ml) was used instead of milk powder to block the membranes during detection of phospho-Ser 485/ Ser 491 α-AMPK. Band intensities were quantified with Fujifilm Multi Gauge software followed by stripping of the membranes with 62.5 mM Tris/HCl buffer (pH 6.7) containing 0.8 % (v/v) 2-mercaptoethanol and 2 % (w/v) SDS for 30 min at 50
• C. The membranes were then re-probed with antibodies against total AMPK α-subunits or total ACC.
Measurements of metabolite contents
Adenine nucleotides in neutralized HClO 4 extracts of frozen myocytes were measured by ion-pair reverse-phase HPLC [13] . Xu5P (xylulose 5-phosphate) in neutralized trichloroacetic acid extracts of frozen myocytes was measured spectrophotometrically. Transketolase was used to catalyse the reaction of Xu5P with ribose 5-phosphate. The resulting glyceraldehyde 3-phosphate was then detected in a NADH-linked coupled assay using triosephosphate isomerase and glycerol-3-phosphate dehydrogenase.
Statistical analyis
All values are shown as means + − S.E.M. for the numbers of independent myocyte preparations (n). Statistical significance was determined by Student's t tests. Unpaired tests were used for adenine nucleotide contents ( Figure 2 
RESULTS
Glucose decreased cardiac myocyte AMPK activity through an adenine-nucleotide-independent mechanism
Measurements of AMPK activity were confined to the α-2 isoform, the dominant form in heart. In order to achieve a condition close to zero glucose for some experiments, cells freshly isolated in 5 mM glucose were washed with glucose-free incubation buffer and were then incubated with various glucose concentrations. This washing, which was as brief as possible to minimize cell stress, was included as a preliminary to all further experiments to maintain comparability of conditions. (Figure 2d ), presumably by catabolic processes. These experiments indicated that increasing glucose could decrease AMPK activity by a mechanism that was independent of changes in adenine nucleotides provided sufficient fuel (glucose or palmitate) was initially present. When AICAR (5-amino-4-imidazolecarboxamide 1-β-D-ribofuranoside) was added to mimic a substantial increase in cellular AMP such as would occur under 'energy stress' conditions, an increase in glucose from 3 to 25 mM caused at least as large a decrease in AMPK activity as that seen between 2 and 25 mM AMPK without AICAR, although the scale of the decrease between 5 and 25 mM glucose was somewhat blunted ( Figure 1e ). This experiment further supported the notion that glucose could decrease AMPK activity independently of its regulation by the cellular energy status.
Glucose decreased phosphorylation of the AMPK site in ACC
The phosphorylation of the AMPK site in ACC-2 (Ser 227 ) was decreased by glucose ( Figure 3) . As controls we also checked that insulin decreased and AICAR increased the phosphorylation of that site.
Glucose and insulin decreased cardiac myocyte AMPK activity by distinct mechanisms
Insulin causes an adenine-nucleotide-independent decrease in cardiac AMPK activity. This is through activation of PKB (protein kinase B) that phosphorylates AMPK α-1/α-2-subunits at Ser 485/ Ser 491 respectively, thereby decreasing the propensity for phosphorylation of the αThr 172 site by upstream AMPK kinases [4] . We investigated whether there might be commonality in the mechanisms through which glucose and insulin decreased AMPK activity. Increasing glucose from 0 to 5 mM decreased AMPK activity by 82 % in both the absence and presence of insulin, whereas insulin decreased AMPK activity by 31 and 33 % at 0 and 5 mM glucose respectively (Figure 4a) . Increasing glucose from 5 to 25 mM decreased AMPK activity by 45 and 41 % in the absence and presence of insulin respectively, whereas insulin decreased AMPK activity by 44 and 40 % at 5 and 25 mM glucose respectively (Figure 4b) . A tendency for the decrease in AMPK activity due to insulin at 5 mM glucose to be very similar to that resulting from an increase in glucose from 5 to 25 mM was consistently observed (also see Figure 7) . A similarity in the scale of these effects was also seen for ACC phosphorylation (Figure 3 We also investigated whether glucose concentration might affect the phosphorylation state of PKB, because Wu et al. [15] had reported that an increase in hepatic fructose 2,6-bisphosphate resulted in an increase in the phosphorylation of PKB. Taken together, these experiments provide no evidence for any commonality in the mechanisms through which glucose and insulin decreased AMPK phosphorylation.
Is the inactivation of AMPK mediated by a glucose metabolite?
Neither 3-O-methylglucose nor 2-deoxyglucose was able to mimic the effect of glucose (see Supplementary Figure S3 at http://www.bioscirep.org/bsr/032/bsr0320229add.htm), suggesting that neither free glucose nor glucose 6-phosphate was likely to be an 'active component' that caused inactivation of AMPK. We also considered the possibility that glycogen might be the 'active component' since the glycogen-binding domain of the AMPK β-subunit inhibits the phosphorylation of AMPK by upstream AMPK kinases [7] . However, myocyte glycogen contents were not significantly altered between 5 and 25 mM glucose (Supplementary Figure S1) , despite there being a consistent decrease in AMPK activity in that glucose concentra- tion range. The myocyte glycogen content of 45-60 nmol of glucosyl units per g wet weight was actually very small compared with the approx. 20 μmol per g wet weight found in rodent skeletal muscle [16, 17] and therefore glycogen may not be important as a regulator of AMPK in cardiac muscle. We considered the possibility that glucose might increase flux though the hexosamine pathway, resulting in O-linked glycosylation of AMPK serine or threonine residues with a concomitant decrease in phosphorylation of these residues [18] . However, azaserine, an inhibitor of O-glycosylation, had no effect on AMPK activity or phosphorylation of αThr 172 (see Supplementary Figure  S4 at http://www.bioscirep.org/bsr/032/bsr0320229add.htm). We also discounted the possibility that pyruvate or lactate might be the 'active component'. When combined with 5 mM glucose, neither compound decreased AMPK activity, and at supraphysiological concentrations both, especially pyruvate, caused the activation of AMPK (see Supplementary Figure S5 at http://www.bioscirep.org/bsr/032/bsr0320229add.htm).
The 'active component' may be an intermediate of the PPP Xylitol, following its oxidation to D-xylulose by D-xylulose reductase, is converted by xylulokinase ino Xu5P, which is a reactant in both of the transketolase-catalysed reactions of the nonoxidative arm of the PPP. In the presence of 5 mM glucose, 1 mM xylitol decreased AMPK activity by nearly 60 % ( Figure 5) ; that is, it was at least as effective in decreasing AMPK activity as an increase in glucose from 5 to 25 mM [see Figures 1(b), 4(b) and 7].
PMS (phenazine methosulfate) that has been used to increase PPP oxidative flux through reoxidation of NADPH [19] [20] [21] decreased AMPK activity (Figure 6a) . By contrast, DHEA (dehydroepiandrosterone), a cell-permeable uncompetitive inhibitor of glucose-6-phosphate dehydrogenase (K i = 6.2-8.9 μM [22] ), increased AMPK activity (Figure 6b) . At 5 mM glucose 30 μM DHEA increased AMPK activity to a level similar to that seen with zero glucose or with AICAR (Figure 1 ), whereas 30 μM PMS decreased AMPK activity to a level similar to that seen with 25 mM glucose (see Figure 7) . Figures 6(c) and 6(d) provided indications that PMS and DHEA had actually altered PPP metabolism. PMS increased the myocyte content of Xu5P 3-fold, suggesting that flux into the non-oxidative arm of the PPP was increased. By contrast, 30 μM DHEA caused almost complete depletion of Xu5P (Figure 6c ). PMS and DHEA, respectively, increased and decreased the yield of CO 2 from [1-
14 C]glucose without significantly altering the yield from [6- 14 C]glucose (Figure 6d) , providing a qualitative indication that PMS and DHEA, respectively, increased and decreased flux through the oxidative arm of the PPP. Figure 7 directly confirms that at 5 mM glucose 30 μM PMS decreased AMPK activity to the level seen with 25 mM glucose alone. Also at 5 mM glucose the effects of insulin and PMS on AMPK activity were largely additive; that is, PMS decreased AMPK activity by 49 and 38 % in the absence and presence of insulin respectively. At 25 mM glucose there was no additivity of these effects.
We tested the effect of thiamine because it is the precursor of the TPP (thiamine pyrophosphate) coenzyme for transketolase and found that it attenuated the effect of glucose on AMPK activity. Thiamine raised AMPK activity so that its decrease between 5 and 25 mM glucose was abolished (Figure 8a ). Thiamine also increased AMPK αThr 172 phosphorylation at 5 mM glucose by 35 % without altering the abundance of AMPK protein [results not shown, P < 0.05 (n = 4)]. The increase in AMPK activity with thiamine was accompanied by increased phosphorylation of ACC to the extent that the decrease in ACC phosphorylation on increasing glucose from 0 to 5 mM was abolished (Figure 8b ).
Quantification of PPP CO 2 production by cardiac myocytes
We wanted to test quantitatively whether PMS and DHEA truly altered PPP oxidative flux, because comparisons of the yields of CO 2 from C-1-and C-6-labelled glucose only provide qualitative indications of changes. Methods to quantify PPP CO 2 formation from glucose by adipose tissue are available in the literature (e.g. [23] ), but these are not applicable to cardiac myocytes where lipogenesis is very low [24] . Therefore we devised an approximation, the 'U/3,4-glucose method', based on the following assumptions. ( (ii) C-3 derived from glucose can emerge as CO 2 via the oxidative arm of the PPP if fructose 6-phosphate derived from transketolase or transaldolase in the PPP non-oxidative arm is recycled back into the oxidative arm of the PPP rather than entering glycolysis. (iii) Anaplerosis, presumed to be through pyruvate carboxylase [25] , makes a small contribution to TCA cycle flux causing some TCA cycle CO 2 to arise from [3,4- 14 C]glucose. By combining data for 25 independent myocyte preparations incubated with 5 mM glucose ( Table 1 ) we found that the calculated PPP CO 2 production of 2.4 + − 1.3 μg atoms of C · h − 1 · (g wet weight)
was just significantly greater than zero (P < 0.05, paired test). However, because some calculated values were negative a significant value could not be deduced from the smaller numbers in the individual experiments 1, 2 and 3. Previously Pfeiffer et al. [26] and Goodwin et al. [27] concluded that PPP flux in isolated working hearts, although not necessarily absent, was very small compared with overall glucose oxidation, and our findings with 5 mM glucose agree with those studies. PMS increased the total oxidation of 5 mM glucose by 1.7-fold with 42 % of this being due to a significant increase in PPP CO 2 formation. DHEA caused a small decrease in the total oxidation of 5 mM glucose together with a significant decrease in the calculated PPP CO 2 formation (experiment 2). Since the myocyte Xu5P content was almost zero with DHEA ( Figure 6c ) we reasoned that PPP CO 2 formation with DHEA ought to be almost zero, in which case the value with DHEA of − 2.5 μg atoms of C · h − 1 · (g wet weight) − 1 in Table 1 indicates the size of the error in the estimation of PPP CO 2 formation at 5 mM glucose. Addition of a correction of 2.5 μg atoms of C · h − 1 · (g wet weight) − 1 gave values of 0, 4.9 and 13.5 μg atoms of C · h − 1 · (g wet weight) − 1 for PPP CO 2 production at 5 mM glucose with DHEA, under basal conditions and with PMS respectively, which in scale closely matched the Xu5P content under these conditions (Figure 6c ). These findings quantitatively support the notion that PMS and DHEA, respectively, increased and decreased PPP oxidative flux. By contrast, thiamine had no significant effect on the total oxidation of 5 mM glucose, on the oxidation of [3,4- 14 C]glucose or on the calculated PPP CO 2 formation (experiment 3). This was as expected since thiamine (or TPP) is not involved in the oxidative arm of the PPP. With 25 mM glucose (experiment 4) PPP CO 2 formation was significantly greater than zero and was not significantly different from that with 5 mM glucose plus PMS. At 25 mM glucose PMS caused a 2.7-fold increase in total glucose oxidation that was mainly due to a 10.6-fold increase in PPP CO 2 formation.
Glucose may decrease AMPK phosphorylation and activity by increasing the activity of an AMPK phosphatase
Both isoforms of the PP2A (protein phosphatase 2A) catalytic subunit are highly expressed in the heart [28] . Endothall, a cell-permeable inhibitor of PP2A, totally abolished the decrease in AMPK activity on increasing glucose from 5 to 25 mM. AMPK activities without endothall at 5 and 25 mM glucose were 6.2 + − 0.5 and 3.8 + − 0.6 pmol · min − 1 per mg of protein respectively (n = 6, P < 0.01), whereas with 25 mM glucose plus 80 nM endothall the AMP activity was 6.2 + − 0.7 pmol · min − 1 per mg of protein. This suggested that activation of PP2A might mediate the effect of glucose on AMPK activity, which would not be at variance with our finding that the glucose effect on AMPK activity was distinct from the PKB-mediated effect of insulin. Adrenaline also decreases myocyte AMPK activity and αThr 172 phosphorylation. That effect is also distinct from the effect of   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . insulin and, like the glucose effect, is abolished when PP2A is inhibited [12] . Figure 9 shows that adrenaline, in addition to causing the expected decrease in AMPK activity, rendered AMPK activity almost totally insensitive to glucose. This suggested some commonality in the glucose and adrenaline effects on AMPK activity. However, the mechanisms cannot be identical because adrenaline decreases AMPK activity equally effectively in the presence and absence of glucose [12] . Also, whereas the effect of glucose is retained in the presence of AICAR (Figure 1e ), the effect of adrenaline is attenuated by AICAR [12] .
Uyeda and co-workers have identified a form of PP2A from liver that is activated 2-3-fold in vitro by Xu5P (half-maximal effect at 10 μM Xu5P) and that plays a glucose-sensing role by selectively dephosphorylating the hepatic 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase bifunctional enzyme and the transcription factor ChREBP (carbohydrate-responsive-elementbinding protein) [29] [30] [31] . The regulatory subunit of this form of PP2A is the Bδ isoform [31] that is highly expressed in the heart [32] . Figure 10 shows that AMPK activity was negatively correlated with Xu5P content and a hyperbolic curve arbitrarily fitted to these data points predicted that AMPK activity equal to 50 % of that seen at zero glucose (or with 5 mM glucose plus DHEA) would be seen at a Xu5P content of approx. 50 nmol · (g wet weight) − 1 . Therefore, in a preliminary experiment, we investigated the effect of Xu5P on myocyte PP2A activity in the expectation that the phosphatase might be activated by Xu5P in the 10-100 μM range as observed in liver. Although we observed an approximate doubling of PP2A activity this was only with Xu5P in excess of the unphysiological concentration of 500 μM ( Supplementary Figure S6 at http://www.bioscirep.org/bsr/032/bsr0320229add.htm). Therefore, although more detailed studies in this area would be of interest, at present there is no evidence to support the notion that Xu5P might be the 'active component', working through an effect on PP2A. Furthermore, other intermediates of the PPP cannot be discounted as possible 'active components' at present.
DISCUSSION
We have shown that changes in PPP activity alter the activity of AMPK in cardiac myocytes and we suggest that an intermediate of the PPP is the 'active component' mediating the dephosphorylation and inactivation of AMPK in response to glucose. Experiments with PMS and DHEA only suggested a role for the PPP in the general sense and did not differentiate between the possibilities of an intermediate of the oxidative arm or of the non-oxidative arm being the 'active component'. Changes in NADPH or NADP + are unlikely to constitute the 'active component' since although both PMS and DHEA should increase the NADP + /NADPH ratio they have opposite effects on AMPK activity. Xylitol and thiamine altered AMPK activity but neither are known to affect PPP oxidative reactions. Therefore we favour the notion that the 'active component' arises from the nonoxidative arm of the PPP.
The dynamics of the cardiac myocyte PPP merit comment. The PPP is usually depicted as combining an irreversible oxidative arm with a freely-reversible non-oxidative arm that interconverts pentose sugar phosphates with glycolytic intermediates thereby allowing the metabolite pool of the non-oxidative arm to be maintained either from glycolysis or through the oxidative reactions of the PPP. However, the content of Xu5P was very severely depleted when glucose-6-phosphate dehydrogenase was inhibited by DHEA indicating that filling of the pool of metabolites in the non-oxidative arm of the PPP must be almost entirely through the oxidative arm of the pathway. An unexpected finding was that, although restrained under normal conditions, the oxidative arm of the PPP in myocytes had an enormous reserve capacity as was demonstrated by increasing glucose concentration from 5 to 25 mM and particularly by the addition of PMS at either glucose concentration (Table 1) . This large reserve capacity could be a key feature of the effective defence that cardiac myocytes can mount against injury by ROS (reactive oxygen species) [33] .
It would be of interest in future to investigate whether there is an inverse link between PPP flux and AMPK activity in tissues that are active in fatty acid synthesis (liver, adipose tissue, lactating mammary gland) or in steroid synthesis (liver, adrenal, gonads). Figure 11 shows a hypothetical PPP/AMPK axis that provides an 'amplification loop'. Increased provision of substrates for ACC or HMG-CoA (3-hydroxy-3-methylglutarylCoA) reductase (e.g. cytosolic acetyl-CoA or HMG-CoA) would increase fatty acid/steroid synthesis resulting in increased PPP oxidative flux because of increased demand for NADPH. If this resulted in an increase in the concentration of the 'active component' a decrease in AMPK activity would ensue, leading to decreased phosphorylation of ACC and HMG-CoA reductase and further enhancement of their activities. Conversely if hepatic fatty acid synthesis was reduced by allosteric inhibition of ACC following an increase in cellular fatty acyl-CoA there would be a decrease in NADPH demand with the PPP/AMPK axis causing increased phosphorylation and inactivation of ACC. Also, direct activation of AMPK following an increase in the cellular AMP/ATP ratio would decrease ACC and HMG-CoA reductase activities, leading to decreased NADPH demand for fatty acid/steroid synthesis. Operation of the PPP/AMPK axis would lead to enhancement of this activation of AMPK. Conversely the PPP/AMPK axis could act to reinforce inactivation of AMPK following a decrease in the cellular AMP/ATP ratio.
Under normal circumstances the ATP that fuels cardiac function is mainly derived from the aerobic catabolism of fatty acids and the carbohydrate fuels glucose, pyruvate and lactate. Fatty acids act both as cardiac fuels and as signals that drive a 'feedforward' activation of their own oxidation. Increased fatty acid concentration results in activation of AMPK leading to increased phosphorylation of ACC, a decrease in malonyl-CoA and deinhibition of CPT-1 [8] . This augments the operation of the Randle Cycle. Conversely, increases in carbohydrate fuels together with an increase in insulin results in decreased fatty acid oxidation and an increase in malonyl-CoA appears to be the key factor in this reverse Randle Cycle effect. The content of malonylCoA in perfused heart or in cardiac myocytes is increased by glucose [11] and it has been suggested that the increase in malonylCoA is due to an increased supply of acetyl-CoA for ACC [34] . We propose that dephosphorylation and activation of ACC in response to glucose (Figure 3 ) additionally contributes to this reverse Randle Cycle effect. We also propose that the classical view of AMPK as a quantitative fuel gauge should be amended to envisage an additional qualitative role in sensing the relative availabilities of the key fuels glucose and fatty acid even under fuel-replete conditions. In addition to decreasing fatty acid oxidation via the ACC/CPT-1 axis an increase in glucose concentration ought to modify the functioning of other AMPK targets in cardiac myocytes. AMPK increases the translocation of the glucose transporter GLUT4 to the cell surface [35] and therefore as in skeletal muscle [6] glucose should auto-regulate its own transport into myocytes. AMPK promotes the translocation of the long-chain fatty acid transporter CD36 to the myocyte cell surface [36] . An effect of glucose to decrease this would enhance the reverse Randle Cycle effect that is driven through the ACC/CPT-1 axis. AMPK phosphorylates TSC2 (tuberous sclerosis complex 2) and Raptor leading to inhibition of mTORC1 (mammalian target of rapamycin complex 1) signalling and suppression of cardiac protein synthesis (reviewed by [37] ). We are unaware of any reports of the effects of glucose increasing mTORC1 signalling as a result of an increase in glucose but a glucose-dependent stimulation of protein synthesis has been noted in heart muscle cells [38] .
Finally, do any of our findings have relevance to cardiac pathology? Cardiac AMPK activity is elevated by hypoxia or ischaemia. At present there is no clear consensus whether AMPK activation is potentially harmful or beneficial to the ischaemic heart (see [39] for a review). If AMPK is harmful it is possible that some of the reduction in mortality after acute myocardial infarction resulting from GIK (glucose, insulin, potassium) infusion therapy [40] is due to the glucose effect on AMPK. Conversely if AMPK activation is beneficial this might explain how inhibition of the PPP oxidative arm protects against ischaemic damage [41] . The attenuation of the glucose effect by adrenaline may also be relevant because there is considerable adrenergic stimulation of the heart during ischaemia [42] . The ability of glucose to decrease AMPK activity through a process that is independent of insulin must be relevant to diabetes. For example db/db mice unexpectedly exhibited decreased cardiac AMPK activity and increased malonyl-CoA content [43] . There is a high incidence of cardiac hypertrophy in diabetic subjects that is only partly the result of a greater degree of hypertension. It would be of interest to investigate whether the glucose effect on AMPK contributed to hypertrophy by lessening the restraint of AMPK on mTORC1 signalling. It has been proposed that some metabolic disorders that are characteristic of Type 2 diabetes may be prevented by pharmacological activation of AMPK [44, 45] . We noted that AICAR did not block the glucose effect on AMPK (Figure 1e) . It would be of interest to discover whether AMPK activators that do not interact with the AMPK γ -subunit AMPK binding site (e.g. A-769662 [3] or PT1 [46] ) can attenuate the glucose effect and thereby be more effective anti-diabetic agents.
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• C with 10 μl of Protein A-Sepharose beads and 2 μl of anti-PP2A catalytic subunit antibody to immunoprecipitate PP2A. The immunoprecipitate was washed twice with lysis buffer and then twice with the assay buffer [50 mM imidazole, pH 7.2, 0.2 mM EGTA, 0.02 % (v/v) mercaptoethanol and 0.1 mg/ml BSA]. After resuspension of the washed immunoprecipitate in 40 μl of assay buffer the reaction was started by the addition of 10 μl of 1 mM phosphopeptide substrate [RRA(pT)VA] with or without 0.1 μM okadaic acid. After incubation at 37
• C for 10 min the reaction was stopped by addition of 50 μl of molybdate-Malachite Green reagent as provided by Promega. After a further 10 min incubation the attenuance was measured at 630 nm. The anti-PP2A antibody was omitted from assay blanks. Although the phosphopeptide is a substrate for all Type-2 protein phosphatases the measurements were specific for PP2A since they were made after immunoprecipitation by an antiserum against the PP2A catalytic subunit. Contamination by PP2B was excluded by the inclusion of EGTA to remove Ca 2 + and contamination by PP2C was excluded by omission of Mg 2 + from the assay. The specificity of the assay is indicated by all of the phosphatase activity being inhibited by okadaic acid in the absence of Xu5P . Apparent okadaic acid-insensitive phosphatase activity in the presence of Xu5P was due to orthophosphate being a minor contaminant of the Xu5P . Open symbols, without okadaic acid; filled symbols, with 0.1 μM okadaic acid.
